MTOR and cancer: At doses higher than 100 nM, CDDO-Me modulates cell differentiation, and at micromolar doses, it exerts cytotoxic, anti-proliferative, pro-apoptotic, and anti-cancer effects [27,33] as the higher concentrations of CDDO-Me affect PI3K/Akt/mammalian target of rapamycin (mTOR), c-Jun NH2-terminal kinase and Janus-activated kinases signaling pathways [29,34,35].